Sign Out
No embryotoxicity or teratogenicity has been observed in animal studies. However, there is no experience of the use of Hyalgan in pregnant women and therefore the expected benefit to the mother should be weighed against any potential risk to the foetus. If Hyalgan is prescribed to a woman of child bearing potential, she should be advised to contact her physician regarding discontinuance of the product if she intends to become, or suspects that she is, pregnant.
Although it is not expected that Hyalgan would be present in human milk, because many drugs are excreted by this route, caution should be exercised when Hyalgan is administered to a nursing mother and the expected benefit to the mother should be weighed against any potential risk to the neonate.
